On the recordJuly 27, 2011
Tell me why we should reauthorize user fees for pharmaceuticals and devices when, in the case of devices, the length of time has gone up since we instituted user fees?
Source
congress.govEditor's note · Context
Questioning the need for reauthorizing user fees due to increased approval times.
Share & report
More from Richard Burr
Jun 15, 2022
I was surprised and frustrated to hear that these funds were overwhelmingly repurposed from within ASPR, including the stockpile.
Apr 4, 2022
The faster, more predictable, and more accountable the programs are, the more patients stand to benefit from lifesaving, innovative drugs and devices.
Jun 15, 2022
Are you beginning to see the pattern as to why a plan is important? This has been a well-orchestrated event up to this point.
Mar 21, 2022
How could you not have passed this into law by now? I mean, this sounds like a panacea.
Other voices in this conversation
